Overview

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

Status:
Terminated
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant. The study will also evaluate the effect of TXA127 on chemotherapy-induced mucositis, an inflammation of the mucous membranes in the digestive tract (mouth to anus) and immune reconstitution which helps patients fight infections. For patients undergoing CBT, both neutrophil and platelet normalization and immune reconstitution can be delayed. TXA127 has shown to be well tolerated by patients and appears to induce a rapid production of neutrophils and platelets in the bloodstream as well as increase the immune system components. It has also been shown to reduce the severity of chemotherapy-induced mucositis.
Phase:
Phase 1
Details
Lead Sponsor:
Tarix Pharmaceuticals
Collaborator:
Constant Therapeutics LLC
Treatments:
Angiotensin I (1-7)